XW0431BIntroduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11

New Technology›Anatomical Regions›Introduction
ICD-10-PCS XW0431B
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

XW0431B is a billable ICD-10-PCS procedure code for Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 018. The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Code Identity

ICD-10-PCS Code
XW0431B
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11
Short Description
Introduce anito-cel in Central Vein, Perc, New Tech 11
Parent Code
XW0

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart4Central Vein
5Approach3Percutaneous
6Device/Substance/Technology1Anitocabtagene Autoleucel Immunotherapy
7QualifierBNew Technology Group 11

In the ICD-10-PCS Alphabetic Index

These FY 2027 ICD-10-PCS Alphabetic Index entries lead to this code:

Iloprost
Leads to this code's table
anito-cel
Anatomy or device term that leads here
Sarilumab
Leads to this code's table
Posoleucel
Leads to this code's table
Rezafungin
Leads to this code's table
Treosulfan
Leads to this code's table
Baricitinib
Leads to this code's table
Sabizabulin
Leads to this code's table
Tocilizumab
Leads to this code's table
Caplacizumab
Leads to this code's table
COVID-19 Vaccine
Leads to this code's table
Inebilizumab-cdon
Leads to this code's table
Sulbactam-Durlobactam
Leads to this code's table
CD24Fc Immunomodulator
Leads to this code's table
COVID-19 Vaccine Dose 1
Leads to this code's table

Browse the full ICD-10-PCS Alphabetic Index →

Code History

FY 2027New code, effective October 1, 2026.
Replaces previously assigned code(s):
  • XW043C7 — Introduce Autolog CAR T in Central Vein, Perc, New Tech 7

Similar Procedure Codes

Questions About XW0431B

Is XW0431B a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11 on inpatient claims from October 1, 2026 through September 30, 2027.

What do the characters in XW0431B mean?

The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character 1 is the Device/Substance/Technology (Anitocabtagene Autoleucel Immunotherapy); the 7th character B is the Qualifier (New Technology Group 11).

What MS-DRG does XW0431B group to?

On an inpatient stay, Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11 maps to MS-DRG 018 (chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies). The MS-DRG sets the fixed Medicare payment for the stay.